JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(2):83-89 | DOI: 10.36290/csf.2020.013

A cost minimization analysis of α2b-interferon supplementation in complex pharmacotherapy of rotavirus infection in newborns

Serhii O. Soloviov1,2,*, Serhii H. Ubohov3, Tetiana A. Aleksandrina1, Olena V. Kovaliuk1, Iryna V. Dziublyk1, Viktor V. Trokhymchuk4, Hlib V. Zahoriy4
1 Virology Department, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
2 Applied Mathematics Department, National Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute", Kyiv, Ukraine
3 Quality Control and Standardization of Medicines Department, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
4 Organizations and Economics of Pharmacy Department, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

Rotavirus is one of the most important causative agents of gastroenteritis in both infants and children worldwide, resulting in high mortality and morbidity, mainly in low-income, developing countries. Respective analysis of medical records of newborns hospitalized with acute gastroenteritis showed that the use of α2b-interferon in complex pharmacotherapy was characterized by faster reverse development of clinical manifestations of the disease than in patients who did not receive interferon. In our study, we also aimed to estimate the effectiveness of α2b-interferon supplementation in combination pharmacotherapy of newborns with suspected rotavirus infection. Achievement of this goal was possible with the construction of a decision tree model and determination of decision rules for inclusion of α2b-interferon supplementation into the complex pharmacotherapy. The input parameters of the model were hospitalization days of patients stratified by such signs as the presence or absence of rotavirus infection, as well as the additional inclusion of α2b-interferon supplementation in complex pharmacotherapy. The criterion for prediction and decision-making was global retrospective rotavirus prevalence. The feature of the simulation was that the costs were expressed as relative to each other, which allowed unifying the proposed methodology. Retrospective analysis of the clinical database of Ukrainian newborns with acute diarrhea has proved that the decision of α2b-interferon supplementation as additional treatment could be cost-saving under 7.4 times its lower price.

Keywords: newborn; Rotavirus infection; interferon; cost minimization analysis

Received: November 1, 2019; Accepted: April 6, 2020; Published: February 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soloviov SO, Ubohov SH, Aleksandrina TA, Kovaliuk OV, Dziublyk IV, Trokhymchuk VV, Zahoriy HV. A cost minimization analysis of α2b-interferon supplementation in complex pharmacotherapy of rotavirus infection in newborns. Čes. slov. farm. 2020;69(2):83-89. doi: 10.36290/csf.2020.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Enserink M. What's Next for Disease Eradication? Science 2010; 330(6012), 1736-1739. Go to original source... Go to PubMed...
    2. Michael J. Selgelid. Smallpox Revisited? Am. J. Bioeth. 2003; 3(1), 5-11. Go to original source... Go to PubMed...
    3. Almond D. Is the 1918 influenza pandemic over? Long-term effects of in utero influenza exposure in the post-1940 US population. J. Political Econ. 2006; 114, 672. Go to original source...
    4. Kelly E. The Scourge of Asian Flu In utero Exposure to Pandemic Influenza and the Development of a Cohort of British Children. J. Hum. Resour. 2011; 46, 669-694. Go to original source...
    5. Dziublyk I., Voronenko S., Mironenko A., Vynograd N. Diagnosis, pharmacotherapy and prevention of influenza, 1st ed. Kyiv: Medknyha 2011.
    6. Dziublyk I.V. Influenza and its prevention: teach. manual, 1st ed. Kyiv: Shupyk KMAPE 2005.
    7. Leleka M. V. Use of modeling in the study of economic burden of influenza in the elderly population in Central and Eastern European countries. Farm. Zh. 2017; 3-4, 34-43. https://doi.org/10.32352/0367-3057.3-4.17.04 Go to original source...
    8. Adda J. Economic Activity and the Spread of Viral Diseases: Evidence from High Frequency Data QJE 2016; 131, 2891-2941. Go to original source...
    9. Pokrovsky V. I. Bricco N. I. Infectious Diseases in the Age of Globalization. Bull. RAMS 2010; 11, 6-11.
    10. Kawai K., O'Brien M. A., Goveia M. G., et al. Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 2012; 30(7), 1244-1254. doi:10.1016/j.vaccine.2011.12.092 Go to original source... Go to PubMed...
    11. Tate J. E., Burton A. H., Boschi-Pinto C., et al. Estimate of worldwide rotavirus-associated mortality in children younger than 5 years old before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12(2), 136-141. doi:10.1016/S1473-3099(11)70253-5 Go to original source... Go to PubMed...
    12. Sergeevnin V. I. Acute intestinal infections. Manifestations of the epidemic process. Physician 2013; 9, 18-20.
    13. Shilov G. Yu. Analysis of the incidence of acute intestinal infections in the Russian Federation, the United States and EU countries. Food Ind. 2013; 10, 50-54.
    14. Lavreonova E. S., Podkolzin A. T., Konovalova T. A., et al. Estimation of the role of conditionally pathogenic flora in the development of acute diarrheal diseases. Infect. Dis. 2012; 10, 53-55.
    15. Lobzin Yu. V. Clinic, epidemiology and prophylaxis of rotavirus infection: methodological recommendations. St. Petersburg: SRICI 2013.
    16. Dziublik I., Nadraga O., Obertynska O., Voronenko S., et al. Viral diseases of guts in children. Collect. Sci. Works Shupyk NMAHE Staff 2008; 17(2), 620-632.
    17. Abaturov A. E., Stepanova Yu. Yu., Krivush O. L., Gerasimenko O. M. Approaches to the treatment of rotavirus infection in children. Mod. Pediatr. 2013; 1(49), 1-4.
    18. Shalamay M. O., Storozhuk I. V. Features of rotavirus infection in young children. Biomed. Biosoc. Anthropol. 2014; 23, 32-135.
    19. Gorelov A. V., Usenko D. V. Rotavirus infection in children. Issues Mod. Pediatr. 2008; 7(6), 78-85.
    20. Dziublyk I. V., Obertinskaya O. V., Kostenko I. G., et al. Rotavirus infection in children of Ukraine. Prophyl. Med. 2009; 2, 34-37.
    21. Soloviov S. O., Mohort H. A., Dziublyk I. V. Determination of age-dependent parameters of the epidemic process of rotavirus infection in Ukraine. Med. Sci. Ukr. 2016; 12(1-2), 72-77.
    22. Soloviov S. O., Mokhort H. A., Trokhimenko O. P., Zahoriy H. V., Trokhymchuk V. V., Kolesnikova I. P., Dziublyk I. V. Pharmacoeconomic and epidemiological bases of optimal rotavirus vaccine supply for Ukrainian population. Wiad. Lek. 2019; 7, 1274-1280. Go to original source...
    23. Dziublyk I. Guide for viral infections chemotherapy: Textbook for Physicians, 1st ed. Kyiv: Shupyk KMAPE 2004.
    24. Shunko Ye. E., Dziublyk I. V, Tunda I. P., Barbova G. I., Kovalyuk O. V. Rotavirus infection in the maternity hospital according to virologic examinations. Ukr. Med. J. 2000; 5(19), 72-75.
    25. Dziublyk I. V. Interferons: nature, mechanisms of action and clinical use of interferon drugs. Child Health 2016; 5, 79-84.
    26. Usacheva O. V., Pakholchuk T. M., Silina E. A., Matveeva T. B., Shulga O. V., Pechugina V. V., Berestova I. V., Stibler A. V., Turlun V. A. Features of the course of rotavirus infection in infants with cytomegaly and approaches to pathogenetic therapy. Mod. Pediatr. 2013; 1, 134-138.
    27. Khalilov Z. S., Yodgorova N. T. Modern methods of diagnosis and treatment of rotavirus intestinal diseases. Re-health J. 2019; 3, 69-90.
    28. Malyshev N. A., Safonova O. A. Rotavirus infection in children: features of the immune response and experience with the use of a new release-active drug. Med. Advice 2016; 7, 70-76. Go to original source...
    29. Feklisova L. V., Meskina E. R., Galkina L. A., Kazakova S. P., Savitskaya N. A., Tselipanova E. E. New approaches to the treatment of viral and bacterial infections in children. Clin. Med. Alm. 2005; 8-1, 338-346.
    30. Tikhomirova O. V., Sergeeva N. V., Sirotkin A. K., Aksenov O. A., Kvetnaya A. S. Viral diarrhea in children: clinical features and treatment tactics. Infant Infect. 2003; 3, 7-11.
    31. Soloviov S. O., Dziublyk I. V., Zaliska O. M., Sakhno G. O. Analytical substantiation of the inclusion of an antiviral drug in the treatment of patients with suspected acute viral diseases. Ann. Mechnikov Inst. 2016; 4, 18-26.
    32. Nemchenko A. S., Balynska M. V. Results of pharmacoeconomic research on the treatment of viral origin enterities in children (on the example of rehydration therapy). Pharm. Chasopys. 2017; 1, 68-73. https://doi.org/10.11603/2312-0967.2017.1.7532 Go to original source...
    33. Laferobion suppositories for 500,000 IU No. 10 (5x2): price in Kyiv https://tabletki.ua/%D0%9B%D0%B0%D1%84%D0%B5%D1%80%D0%BE%D0%B1%D0%B8%D0%BE%D0%BD/22248/pharmacy/?s=price (02. 04. 2020).

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.